Strong menopause data for Remifinim

13 August 2006

A recent study published in the Archives of Internal Medicine concluded that, while "alternative and complementary therapies are generally ineffective for treating menopause-related symptoms," Remifemin, a herbal prepration of the black cohosh root, elicited clear symptomatic relief.

The July 24 review article was welcomed by USA-based Enzymatic Therapy, a provider of therapeutic-dosage natural medicines and nutritional supplements. Remifemin is its proprietary, standardized extract (uniform dosage) of pure black cohosh root called RemiSure, which it claims is the most obstetrician/gynecologist-recommended non-prescription brand of menopause treatment.

The clinical reviewers wrote that "a single large trial showed a benefit for vasomotor symptoms with the black cohosh Remifemin," which is "consistent with older German studies," adding that results from two studies "were confounded by concurrent use of tamoxifen, known to exacerbate hot flashes," while another used a "more unusual (research) preparation, BN01055."

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight